Boehringer To Acquire Trutino Under Aggressive Cancer R&D Strategy

Remains Mum On Numbers

The family-owned German firm plans to purchase all shares of current partner, Trutino, to gain its systematically delivered cytokine portfolio amid a broader push to diversify and improve its oncology offering.    

Boehringer's Recent Deals Have Focused On Precision Cancer Medicines • Source: Shutterstock

Boehringer Ingelheim GmbH has signed an option to acquire partner Trutino Biosciences, Inc. for its next-generation ‘on-demand’ cytokine platform, marking its second deal this month aimed at bulking up its oncology pipeline.

Boehringer has retained the right to buy all shares of Trutino upon the completion of certain program milestones within a given timeframe and the target will continue to operate as an independent firm in the meantime. The transaction will include an option fee, the issuance of a convertible note and fixed purchase price terms

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

More from Business

In Brief: US FDA Delay Sends Biohaven Shares Down

 

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

In Brief: Sanofi Commits $20bn To US R&D And Manufacturing By 2030

 

Move by French major aligns with broader industry efforts to localize production amid political pressure, as Trump pushes to onshore manufacturing and hints at easing tariff threats.

Eisai Forecasts 73% Leqembi Sales Rise In FY25 As Demand Expands

 
• By 

Eisai spent most of its FY24 earnings call discussing plans for growing sales of Biogen-partnered Alzheimer’s drug Leqembi from JPY44.3bn ($304.1m) to JPY76.5bn ($525.1m) in FY25.